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ABSTRACT 
Background: PPIs are the most commonly used drugs in clinical practice; 
inappropriate prescribing may result in increased therapeutic load and treatment 
cost as well. Hence, a study was conducted to determine the prescribing pattern 
(rationality and irrationality) of both iv and oral PPIs in tertiary care teaching 
hospital and cost minimization process can be used only to compare two products 
that have been shown to be equivalent in dose and therapeutic effect. 
Aim and Objective:  
 To analyze the prescribing pattern of Proton pump inhibitors. 
 To assess the rationality of prescribing oral and iv Proton pump 
inhibitors. 
 To estimate the cost of iv and oral Proton pump inhibitors. 
Method: A retrospective observational study was carried out in a multispecialty 
tertiary care hospital on patients’ medical records from Department of 
Gastroenterology and Department of general surgery. The study sample size were 
341, the exclusion criteria were patients who did not receive Oral and IV PPIs 
and patients under 18 years old. The cost of the prescribed PPI brands is 
compared with the cost of other available brands in the hospital pharmacy. 
Results: Most of the patients were seen under the age category between 41-60 
years (62.8%). The majority of the patients were Male in this study (69.5%). 
Most of the patients were included from the Department of Gastroenterology 
(63.3%). Pantoprazole was administered in a majority of 308 patients (90.3%). 
Indication for giving PPIs in 181 Patients were Multi-drug use (53.1%) which 
was majority. 208 patients received PPI through intravenous route (61%). Most 
of the patients in the study received PPI for a duration of 4 days in 65 patients 
(19.1%). 282 patients received rational therapy (82.7%) which was a greater 
extent. Pan 40 (Pantoprazole) was seen to be the most prescribed brand in this 
study. The cost of pan 40 was reasonable compared to the other prescribed 
brands. However, Omez (Omeprazole) was the prescribed brand with least cost. 
Abstract 
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Conclusion: Pantoprazole was the most prescribed PPI in this study. There are 
only considerable differences between PPIs in terms of clinical efficacy, the 
possible drug interactions could be a key factor in the selection of PPIs. In 
addition, utmost care should be taken while administering PPIs in patients 
receiving multiple drugs and other elder patients prone to take combination of 
drugs to attain a rational therapy. PPIs proven to have lower risks of drug 
interaction would be the favorable choice in those occasions. 
 
Introduction 
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INTRODUCTION 
 
Proton Pump Inhibiitors (PPIs) remain the superior choicein the evidence-based 
treatment  of gastrointestinal disorders which include peptic ulcer disease (PUD), 
dyspepsia, gastro esophageal reflux disease (GERD),eradication of Helicobacter pylori 
(in combination with antibiotics), controlling excessive acid secretion in Zollinger–
Ellison syndrome and hypersecretory state, and prevention of ulcers due to nonste-
roidal anti-inflammatory drugs (NSAIDs).They are also used for a number 
ofunlicensed indications (morecommon in hospital settings), including the reduction of 
re-bleeding episodes aftertreatment of severe peptic ulcer bleeding, prophylaxis of acid 
aspiration during generalanesthesia and stress ulcer prophylaxis.
(1)
 
PPIs class includes the following drugs: Lansoprazole, Omeprazole, 
Pantoprazole,Rabeprazole and Esomeprazole.The differences between the PPIs in 
terms of clinicalefficacy and safety are fairly minimal. 
 
A) Indications of PPIs: 
 
PPIs are prescribed for the previously mentioned indications, but when a patient 
presented with dyspepsia are initially prescribed non-pharmacological therapy, such as 
to follow simple lifestyle changes which include weight reduction, healthy eating, 
smoking cessation and avoiding diet or beverage ingredients that associated with 
stimulation of dyspepsia such as alcohol, coffee, chocolate and fatty foods. It’s 
strongly recommended that the patient should eat well before 3 to 4 hours from 
bedtime and raise the head of the bed may also be beneficial. If the response in not well 
enough, the first line treatment should be alginate either “as required” or regularly. 
PPIs should only be prescribed for short courses (4 weeks) where needed. If symptoms 
persist or recur, a PPI can be continued at the lowest dose possible to control symptoms 
or on basis of as-required. 
PPIs are generally well tolerated, and the side effects are usually mild and reversible, 
including headache, diarrhea, abdominal pain, nausea, constipation, skin rashes and 
dizziness. There are, however, growing concerns about a variety of adverse effects 
with long term PPI use as listed as following:
(2) 
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1) Vitamin B12Deficiency 
2) Vitamin C deficiency 
3) Mineral deficiencies:  
I. Calcium deficiency  
II. Magnesium deficiency 
III. Iron deficiency 
4) Rebound hypersecretion syndrome 
5) Risk of Acute interstitial nephritis (AIN) 
 
1) Vitamin B12Deficiency: 
   The main food sources for vitamin B12 (water-soluble vitamin) include meats, fish, 
poultry, eggs and dairy products. Vitamin B12 absorption depends on peptic enzymes 
to cleave dietary B12from dietary proteins. This process is performed primarily by 
pepsin, which needs gastric acid for its activation from pepsinogen precursor. Without 
gastric acid, vitamin B12would not be cleaved from dietary protein and would not be 
able to bind to R-proteins, which in turn protect vitamin B12from pancreatic digestion. 
Theoretically, acid suppression may lead to malabsorption and eventually vitamin 
B12deficiency. But the common human storage of the vitamin B12 is quite enough to be 
depleted minimum more than one year. It has been estimated that vitamin B12 
deficiency affects up to 20% of the elderly, and has been linked to impaired 
gastrointestinal absorption syndromes and pernicious anemia. The results from these 
trials have not yielded consistent data to create either therapeutic guidelines or to offer 
recommendations for routine dietary supplementation. 
 
 
 
2) Vitamin C deficiency: 
PPIs affect vitamin C bioavailability through decreasing its concentration in gastric 
juices and its proportion of vitamin C in its active antioxidant form, ascorbic acid. A 
previous study investigated the effect of omeprazole 40 mg for 4 weeks on vitamin C 
          Introduction 
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concentrations in gastric juice in both healthy individuals and subjects. Median 
intragastric pH increased from 1.4 before omeprazole therapy to 7.2 while subjects 
were taking omeprazole, and vitamin Cconcentrations decreased from 5μm/l to 3μm/l 
reflecting a notable decrease in the biologically active form of ascorbic acid. 
3) Mineral deficiencies  
I- Calcium deficiency  
There is conflicting evidence regarding to the role of intragastric hydrochloric acid in 
calcium absorption. In one study proposed that both stomach acid and the slightly 
acidic medium of the proximal duodenum are important to facilitate calcium 
dissociation from ingested food, making it available for absorption.  In The contrary in 
another study found that gastric acid secretion and gastric acidity do not normally play 
a role in the absorption of dietary calcium. Several trials implicating treatment with PPI 
as leading to an increased risk of osteoporotic fracture has raised a critical analysis of 
the possible relationship, suggesting a causal relationship.  In 2010, the US FDA 
released a warning revising the prescription and OTC labels for PPIs to include new 
safety information regarding a potential increased risk of fractures of the hip, wrist and 
spine with the use of these medications. 
II- Magnesium deficiency: 
All PPIs has been reported and documented to cause hypomagnesaemia that are 
biochemically substituted pyridyl-methylsulphonylbenzimidazadole derivatives, in the 
following order of potency: Rabeprazole, Esomeprazole, Omeprazole, Lansoprazole 
and Pantoprazole. In 2011, the US FDA released a warning based upon several 
published case reports stating that PPIs may cause hypomagnesaemia if taken for more 
than one year. 
III- Iron deficiency: 
     It has been reported that PPI therapy results in clinically significant iron 
malabsorption due to gastric acid hyposecretion. Dietary iron is present in food in 
either the following forms; heme iron (32%) or nonheme (66%), and absorption of 
nonheme iron is markedly improved by gastric acid. The role of gastric acid assists 
          Introduction 
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food sources containing nonheme iron to dissociate and to solubilize the iron salts, 
resulting in formation of complexes with sugars and amines facilitating absorption. 
 
4) Rebound hypersecretion syndrome: 
NICE confirms that long term treatment with PPI has been linked to rebound 
hypersecretion,and states that: “This may exacerbate symptoms once PPI therapy is 
discontinuedalthough this is a theoretical concern as there are no data that support acid 
rebound as a clinical problem in patients”. Therefore it is recommended that all 
patients receiving PPIs should be offered anannual review and are encouraged to taper 
down from treatment gradually where appropriate.   
 
5) Risk of Acute interstitial nephritis (AIN): 
 AINis an uncommon side effect of PPIs. In a previous study undertaken in four cases 
where the following PPIs were implicated (pantoprazole omeprazole and esomeprazole 
in one each), AIN developed after an average period of 4 weeks of drug therapy. PPI 
was stopped and steroids were initiated in all patients. ANI was successfully reversed 
totally in two patients and partial in the rest two. So an attention is needed to suspect 
ANI induced by PPIs.
(5)
 
 
B) Prescribing patterns and rational prescribing(3) 
It is known that rational prescribing of medication is assurance that the patient receives 
the appropriate medication according to his/her medical needs in a dose and route of 
administration meet the condition requirement for adequate period of time. In previous 
study had reported that prescribing of PPIs was estimated over 60% were for 
hospitalized patients. The Medical council of India in a notification at New Delhi, in 
11
th
 of March-2002, clearly stated that every physician should prescribe drugs with 
generic names and he/she shall ensure that there is a rational prescription and use of 
drugs. 
 
The comparison in the difference in the efficacy between oral versus intravenous PPIs 
was done by a pervious study in the treatment of peptic ulcer treatment. This study 
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reached for the result that oral PPIs demonstrated similar effectiveness to intravenous 
PPIs among patients with peptic ulcer bleeding. 
Over prescribing of IV PPIs is associated with in increased shortages of IV PPIs in 
hospitals, therapeutic burden on patients, increased frequency of adverse effects, and 
increased treatment costs. A study examined the inappropriate use of intravenous PPIs 
.The result showed that there was significant inappropriate PPIs administration with 
reference to indication to use, duration of therapy, and changeover of therapy. 
 
Methods to evaluate patterns of drug use in hospitals: 
 Prescription and physician surveys,  
 Analysis of drug sales or drug consumption data,  
 Reviews of medical records. 
 
C) Pharmacoeconomics 
    Pharmacoeconomics is the science concerned with the comparisons of costs & 
consequences/outcomes of drug therapies. It adopts and applies principles and 
methodology of health economics.Pharmacoeconomics is essential for pharmaceutical 
policy and decision making. And it can be used effectively by a pharmacist to 
improvise the efficiency of his profession.
(6)
 
Types of Pharmacoeconomics Analysis: 
1) Cost Minimisation Analysis(CMA). 
2) Cost Effective Analysis (CEA) 
3) Cost Utility Analysis (CUA). 
4) Cost Benefit Analysis (CBA). 
Cost analysis of PPIS: 
The most commonly used cost analysis is Cost-Minimization Analysis (CMA) which 
simply compare two the price of two medicines with equal effectiveness. CMAis 
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accurate method when comparing cost between two therapeutically equivalent 
medicines. The following diagram demonstrate the steps of CMA. 
Steps of CMA 
 
 
 
 
Obtain acquisition price for each medicine and 
calculate the price for the course of treatment to be 
compared—dose per day, number of days of 
treatment. 
Calculate pharmacy, nursing, and physician 
costs associated with the use of each medicine. 
Calculate equipment cost associated with each 
medicine. 
Calculate laboratory cost associated with each 
medicine. 
Calculate and compare total medicine costs for 
each medicine. 
Background  
Background 
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BACKGROUND 
PPIs are the most commonly used drugs in clinical practice; inappropriate 
prescribing may result in increased therapeutic load and treatment cost as well. 
Hence, a study was conducted to determine the prescribing pattern (rationality 
and irrationality) of both iv and oral PPIs in tertiary care teaching hospital and 
cost minimization process can be used only to compare two products that have 
been shown to be equivalent in dose and therapeutic effect. 
There is growing concern with the rapid increase in prescribing proton 
pump inhibitor drugs (PPIs), (In 2006 PPI was the third most frequently 
prescribed drug in Australia. In United States, UK and New Zealand similar 
trends were observed), for a variety of gastrointestinal disorders, (gastro-
esophageal reflux disease, dyspepsia, peptic ulcer disease, NSAID-induced ulcer, 
eradication of Helicobacter pylori, and hyper secretory disorders), and the 
escalating costs associated with this trend. The study have included that general 
practitioners (GPs) prescribe PPIs irrationally and that patients demand PPIs and 
use them as a way of avoiding having to make lifestyle changes. The present 
study was planned with the aim of finding out the rational use of proton pump 
inhibitors (PPIs) in the patients. 
A retrospective observational study of PPIs was conducted for a period of 
six months in the patients of gastroenterology and surgery departments who were 
more than 18 years of age and who were receiving i.v and oral (PPIs) were 
included in the study; paediatric patients and out patients were not enrolled in the 
study. All the details of each patient was collected from patient’s case notes, 
treatment chart and evaluated for appropriateness regarding indications. 
    Literature Review 
Literature review 
 
PSG College of Pharmacy Page 10 
 
LITERATURE REVIEW 
 
1- Nasrin Shahsavani, D. R Raju Koneri, Balakeshawa Ramaiah, Shibi 
Mary Thomas, Assessment of prescribing Pattern of proton Pump 
inhibitor and histamine 2 receptor antagonist,  Journal of 
Innovations in Pharmaceuticals and Biological Sciences, e-ISSN: 
2349-2759 p-ISSN: 2395- 1095 
 
 Proton Pump Inhibitors (PPIs) remain the leading evidence based therapy 
for upper Gastro intestinal disorders, including gastro-esophageal reflux disease, 
dyspepsia, peptic ulcer disease, NSAID-induced ulcer, eradication of 
Helicobacter pylori, and hyper secretory disorders. H2 receptor antagonists like 
ranitidine is the first choice H2 receptor antagonist in most patient. Our study 
aimed about the assessment of the prescribing pattern of PPIs and H2 receptor 
blockers. Our other objectives were to assess therapeutic appropriateness with 
standard guideline, ADR &Drug Interactions related to PPI &H2 receptor 
antagonist. Our study was a prospective observational study, included 209 
patients, was conducted in a tertiary care Bangalore Baptist Hospital, Bangalore, 
INDIA for a period of six months. The results of this study observed that males 
were more using PPIs than females. Therapeutic appropriateness was mostly 
correct among both PPIs and H2 receptor blockers. We can conclude that 
continuous medical education with focus on rational drug use and evidence based 
medicine should form part of the program of the hospital. They should be 
involved in collection and presentation of prescribing data as part of clinical audit 
and also education of patients/caretakers. Also hospitals should consider 
developing controlled policies like formulary restriction, stop orders for specific 
indications, and automatic switch-order to oral PPI if patient is receiving oral 
feeding. This study could provide direction for much needed randomized 
controlled trials evaluating the use of PPIs in the first year of life, including 
specific recommended dosing, duration of therapy, and effectiveness of 
treatment. 
 
2- K. Sampathkumar, R. Ramalingam, A. Prabakar, and A. Abraham, 
Acute interstitial nephritis due to proton pump inhibitors, Indian J 
Nephrol. 2013  
       
     Proton pump inhibitors (PPI) are commonly prescribed for dyspepsia and acid 
peptic disease. Acute interstitial nephritis (AIN) is an uncommon though 
important sideeffect of these classes of drugs. We describe four cases: three 
females and one male. PPIs implicated were pantoprazole in two, omeprazole and 
esomeprazole in one each. AIN developed after an average period of 4 weeks of 
drug therapy. The symptoms were vomiting, loin pain, and oliguria. Minimal 
roteinuria with pyuria were seen and the mean serum creatinine was 4.95 ± 4 
Literature review 
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mg/dl. Two patients required hemodialysis. Renal biopsy showed interstitial 
mononuclear, plasma cell and eosinophilic infiltrates in all cases. PPI was 
stopped and steroids were started in all. Renal recovery was total in two and 
partial  
in two. A high index of suspicion is required to diagnose PPI induced AIN. Renal 
biopsy for confirmation followed up by prompt steroid therapy results in renal 
functional improvement. 
 
 
3- Elaine W. Yu, MD1, Scott R. Bauer, BS2, Paul A. Bain, PhD3, and 
Douglas C. Bauer, MD4, Proton pump inhibitors and risk of 
fractures: a meta-analysis of 11 international studies, NIH Public 
Access, Am J Med. 2011 June ; 124(6): 519–526. 
doi:10.1016/j.amjmed.2011.01.007. 
 
  In this meta-analysis of observational studies, PPIs modestly increased the risk 
of hip, spine, and any-site fractures, whereas H2RAs were not associated with 
fracture risk. The possibility of residual confounding cannot be excluded. Further 
skeletal evaluation should be considered for patients who are taking PPIs and are 
also at risk for osteoporotic fracture. 
 
 
4- K. K. F. Tsoi*,†,‡, H. W. Hirai* & J. J. Y. Sung*, Meta-analysis: 
comparison of oral vs. intravenous proton pump inhibitors in patients 
with peptic ulcer bleeding, Alimentary Pharmacology and 
Therapeutics, 2013; 38: 721-728 ª 2013 John Wiley & Sons Ltd  
 
        Oral PPIs demonstrate a similar effectiveness to intravenous PPIs among 
patients with peptic ulcer bleeding, but the results were combined from open-
labelled trials with limited sample size. A large double-blind noninferiority trial 
is required to better assess the role of oral PPIs. 
 
 
5- Joel J. Heidelbaugh,  Proton pump inhibitors and risk of vitamin and 
mineral deficiency: evidence and clinical implications,  Therapeutic 
Advances in Drug Safety, (2013) 4(3) 125–133 
 
        Proton pump inhibitors (PPIs) remain the superior choice worldwide in 
antisecretory therapy in the evidence-based treatment of upper gastrointestinal 
disorders including gastroesophageal reflux disease, erosive esophagitis, 
dyspepsia and peptic ulcer disease. PPI overutilization in ambulatory care settings 
is often a result of failure to re-evaluate the need for continuation of therapy, or 
insufficient use of on-demand and step-down therapy. Nonjudicious use of PPIs 
creates both preventable financial as well as medical concerns. PPIs have been 
associated with an increased risk of vitamin and mineral deficiencies impacting 
vitamin B12, vitamin C, calcium, iron and magnesium metabolism. While these 
risks are considered to be relatively low in the general population, they may be 
notable in elderly and malnourished patients, as well as those on chronic 
hemodialysis and concomitant PPI therapy. No current evidence recommends 
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routine screening or supplementation for these potential vitamin and mineral 
deficiencies in patients on either short- or long-term PPI therapy. Reducing 
inappropriate prescribing of PPIs can minimize the potential risk of vitamin and 
mineral deficiencies. 
 
 
6- Jarchow-Macdonald AA1, Mangoni AA, Prescribing patterns of 
proton pump inhibitors in older hospitalized patients in a Scottish 
health board, , 2013 Oct;13(4):1002-9Geriatr Gerontol Int. 
 
     Inappropriate PPI prescribing is common in frail older hospitalized 
patients, and might increase the risk of drug-drug interactions. Polypharmacy 
and comorbidity were independently associated with inappropriate PPI 
prescribing in this group. 
 
7- P. F. Haastrup, Rasmussen , J. M. Hansen ,R. D. Christensen , 
J. Søndergaard
 
 and D. E. Jarbøl General practice variation when 
initiating long-term prescribing of proton pump inhibitors: a 
nationwide cohort study, BMC Family PracticeBMC series, 
201617:57 
      Practice characteristics such as GP age and gender could explain some of the 
observed variation in prescribing patterns for PPIs. This variation may indicate a 
potential for enhancing rational prescribing of PPIs. 
  
 
8- Mark Reid, MD1,2*, Angela Keniston, MSPH1, Inappropriate 
Prescribing of Proton Pump Inhibitors in Hospitalized Patients, 
Journal of Hospital Medicine Vol 7 | No 5 | May/June 2012 
 
      Proton pump inhibitors are frequently inappropriately prescribed to Medicine 
inpatients who do not have a valid indication and this practice is associated with 
an increase in C. difficile infection. Interventions are needed to curtail this 
inappropriate prescribing practice. 
 
 
9- N.M. Walker, J. McDonald, An evaluation of the use of proton pump 
inhibitors, Pharmacy World and Science, June 2001, Volume 23, 
Issue 3, pp 116–117 
           Frequent review of therapy and improved communications between 
primary and secondary care are vital to rationalise the use of PPIs and to reduce 
expenditure. 
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10- Soumana C Nasser, Jeanette G Nassif, and Hani I Dimassi, Clinical 
and cost impact of intravenous proton pump inhibitor use in non-ICU 
patients, World J Gastroenterol. 2010 Feb 28; 16(8): 982–986 
      This study highlights the over-utilization of IV PPIs in non-intensive care unit 
patients. Restriction of IV PPI use for justified indications and route of 
administration is recommended. 
 
 
11- Mohammed S. Alsultan, Ahmed Y. Mayet,  Areej A. Malhani,  and 
Mashael K. Alshaikh
, 
Pattern of Intravenous Proton Pump Inhibitors 
Use in ICU and Non-ICU Setting: A Prospective Observational Study 
       Inappropriate IV PPI utilization was predominant in non-ICU patients, 
mostly for stress ulcer prophylaxis that leads to a waste of resources. 
Applying appropriate policies, procedures and evidence-based guidelines, 
educated physicians and surgeons can clearly limit inappropriate IV PPI use. 
 
12- Joanna K. Law, Chris N. Andrews, Robert Enns, Intravenous proton 
pump inhibition utilization and prescribing patterns escalation: a 
comparison between early and current trends in use,GIE,  Volume 
69, Issue 1 
        IV PPI use has escalated at our hospital and is being prescribed in 
patients before endoscopy with fewer patients noted to have HRES on 
endoscopy. 
 
13- Jacob G. Hoove, Annabel L. Schumaker, Kevin J. Franklin, Use of 
Intravenous Proton-Pump Inhibitors in a Teaching Hospital Practice, 
Digestive Diseases and Sciences, September 2009, Volume 54, Issue 9 
    Intravenous PPI prescribing habits in this military hospital facility are 
poor. A multifaceted approach including physician/pharmacist education, IV 
PPI ordering templates, and a consensus medical position statement from a 
major gastroenterological or prominent medical association may lead to 
more appropriate use. 
 
14- Mandana Moradi, Samaneh Raeesi and Zahra Sepehri, Audit of IV 
pantoprazole: pattern of administration and compliance with 
guideline in a teaching hospital, , 
SpringerPlusSpringerPlus20165:1749 
Literature review 
 
PSG College of Pharmacy Page 14 
 
     We concluded that although establishing guideline was successful in reducing 
the overall rate of IV pantoprazole administration and its related costs, different 
contributing factors halted its effect on correcting the prescribed dosage and 
indications, especially as the time gaps from guideline establishment. This fact 
magnifies the importance of continuous educations of prescribers about the 
importance of evidence based practice and need for and implementing a powerful 
executive supervisory in our hospital. 
 
15- Ghias Ul Hassan, Israr Ul Haque*, Muhammad Asim Hameed, 
PRACTICES OF PROTON PUMP INHIBITORS USE IN 
MEDICAL WARDS, Pak Armed Forces Med J 2017; 67 (4): 524-28  
PPIs are over used without clear indications in hospitalized and 
discharged patients. 
 
Aim & Objectives 
Aim and objective 
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AIM AND OBJECTIVE 
 The study is concerned with monitoring of PPI prescribing patterns in order to:  
 To analyze the prescribing pattern of proton pump inhibitors 
 To assess the  rationality of prescribing oral and  iv proton pump 
inhibitors 
 To estimate the cost of the  iv and oral proton pump inhibitor 
 
Plan of Study 
Plan of study 
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PLAN OF STUDY 
PHASE I: 
 Preliminary literature search 
 Designing study protocol 
 Data collection form 
 
PHASE II:  
 Literature survey 
 Data collection 
 Data analysis 
 
PHASE III: 
 Result and discussion 
  
 
Methodology 
Methodology 
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METHODOLOGY 
Study design: 
 Retrospective observational study. 
Study location: 
The study was carried in a multispecialty tertiary hospital, on inpatients 
medical records from gastroenterology and surgery ward. 
Study Approval: 
The protocol of study submitted to institution of human ethics committee 
(IHEC,PSG IMSR) of the hospital. The protocol was approved with proposal 
number: 17/153 on 25.04.2017 . 
Sample size: 
 341 patients who received PPIs. 
The total number of patients in the respected two wards who was 
prescribed PPI was 2987 patient for the period of six months. By applying the 
RAOSFT program the sample size calculated to be 341 patient with the margin of 
error 5% and confidence level of  95%.   
Study duration: 
Six months. 
 
Inclusion criteria: 
 Male and female patients 
 Patients received oral/ IV PPI 
 Patient over 18 years old 
 
Exclusion criteria: 
Methodology 
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 Patients don’t receive oral and IV PPI.  
 Patient under 18 years old 
 
Methodology: 
Recruitment of subjects according to the inclusion and exclusion criteria 
 
Data collection 
 
Analyze the PPI,s 
 
Assess the rationality 
 
Cost benefit studies 
 
Result and conclusion 
 
Statistical analysis: 
The data was analyzed by Percentage analysis.   
Results  
Results 
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RESULTS 
AGE 
 The study included 341 patients. Out of them, 146 patients were observed 
from the age group between 41-60 years old (42.8%), then 111 patients were 
above 60 years old (32.8%) and 84 patients of age between 18-40 years (24.6%). 
Most of the patients were seen under the age category between 41-60 years. 
Table-1: Age wise distribution 
Age Frequency Percent 
18-40 84 24.6 
41-60 146 42.8 
60+ 111 32.6 
 
Figure-1: Age category v/s Frequency and percent 
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Gender 
 Out of 341 patients in the study, 237 patients were Male (69.5%) and 104 
patients were female (30.5%). The majority of the patients were Male in this 
study. 
Table-2: Gender 
Gender Frequency Percent 
Female 104 30.5 
Male 237 69.5 
 
Figure-2: Gender v/s Frequency and percent 
 
Department 
 Among 341 patients included in this study, 216 patients were from 
Department of Gastroenterology (63.3%) and remaining 125 were from 
Department of Surgery (36.7%). Most of the patients were included from the 
Department of Gastroenterology. 
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Table-3: Department 
Department Frequency Percent 
Gastroenterology 216 63.3 
Surgery 125 36.7 
 
Figure-3: Department v/s Frequency and distribution 
 
 
 
PPI used 
 Among 341 patients in the study, Pan was administered in 308 patients 
(90.3%) followed by Rablet in 18 patients (5.3%), Esomac in 10 patients (2.9%), 
Omez in 4 patients (1.2%) and Rabicip in 1 patient (0.3%). 
 
Table-4: PPI used 
Name of PPI Frequency Percent 
Esomac 10 2.9 
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frequency
percent
Department 
surgery
gastroenterolgy
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Omez 4 1.2 
Pan 308 90.3 
Rabicip 1 0.3 
Rablet 18 5.3 
 
Figure-4: PPI used v/s Frequency and percent 
 
 
 
Indication 
 Out of 341 patients, Indication for giving PPI in 181 Patients were 
received PPIs for Co-morbidities (53.1%) which was majority followed by 
Analgesic in 42 patients (12.3%), Gastritis in 27 patients (7.9%), GERD in 20 
patients (5.9%), Peptic ulcer in 7 patients (2.1%), UGI bleeding in 5 patients 
(1.5%). PPIs were administered in the remaining 59 patients (17.3) for without 
indications.  
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Table-5: Indication 
Indication Frequency Percent 
Gastritis 27 7.9 
GERD 20 5.9 
Co-morbidity 181 53.1 
Analgesic 42 12.3 
Peptic ulcer 7 2.1 
UGI bleeding 5 1.5 
Without indication 59 17.3 
 
Figure-5: Indication v/s Frequency and percent 
 
 
Route of Administration  
 Out of 341 patients included in the study, the majority of 208 patients 
were received PPI through intravenous route (61%) and 133 patients received 
through Oral route (39%).  
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Table-6: Route of Administration 
Route of Administration Frequency Percent 
IV 208 61.0 
Oral 133 39.0 
 
Figure-6: Route of Administration v/s Frequency and Percent 
 
 
 
Duration 
 Among 341 patients in this study, most of the patients received PPI for a 
duration of 4 days in 65 patients (19.1%) followed by duration of 5 days in 52 
patients (15.2%), duration of 3 days in 43 patients (12.6%), duration of 6 days in 
34 patients (10%), duration of 7 days in 31 patients (9.1%), duration of 2 days in 
29 patients (8.5%), duration of 8 days in 20 patients (5.9%), duration of 9 days in 
13 patients (3.8%) and duration of 1 day in 7 patients (2.1%). Remaining 47 
patients received PPI for 10 days and above up to 21 days. 
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Table-7: Duration 
Duration (days) Frequency Percent 
1 7 2.1 
2 29 8.5 
3 43 12.6 
4 65 19.1 
5 52 15.2 
6 34 10 
7 31 9.1 
8 20 5.9 
9 13 3.8 
10+ 47 13.8 
 
 
Figure-7: Duration v/s Frequency and percent 
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Rationality 
 Out of 341 patients included, 282 patients received rational therapy 
(82.7%) and 59 patients received irrational therapy (17.3%). 
 
Table-8: Rationality 
Rationality Frequency Percent 
Rational 282 82.7 
Irrational 59 17.3 
 
 
Figure-8: Rationality v/s Frequency and distribution 
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COST ANALYSIS 
 
Table No: 9 
 
 Pan 40 was the brand among pantoprazole which was of least 
cost available in the hospital. The other available brands; Pantodac, 
Pantium and Pantocid are costlier than the prescribed brand. 
Esomeprazole was having other available brands in the hospitalof 
lesser cost. Brand Reciper injection, Nexpro tablet and Sompraz 
injection were respectively 0.50, 0.75 and 4.50 rupees lesser than 
brand Esomac. Among the available 2 brands in Omeprazole, the 
prescribed brand was Omez which is Rs.0.60 less costly than 
available Omicap. Rablet 40 and Rabicip were the brands prescribed 
for the drug Rabeprazole while other lesser brands were available. 
Veloz 20 and Razo 20 are respectively Rs.2.84 and Rs.1.90 costlier 
than the prescribed brand. 
 
S.No 
Generic 
name 
Brand 
prescribed 
Cost of 
prescribed 
brand 
Other 
available 
brands 
Cost of 
available 
brand 
Difference in 
cost 
Oral iv Oral iv Oral iv 
1 Pantoprazole Pan 40 8.00 44.00 
Pantodac 9.60 45.25 +1.60 +1.25 
Pantium 8.70 - +0.70 - 
Pantocid 8.65 49.76 +0.65 +5.76 
2 Esomeprazole Esomac 6.80 83.00 
Raciper 6.80 82.50 0.00 -0.50 
Nexpro 7.55 93.40 -0.75 +10.4 
Sompraz 6.80 78.50 0.00 -4.50 
3 Omeprazole Omez 3.84 31.88 Omicap 4.43 - +0.60 - 
4 Rabeprazole 
Rablet 40 9.29 91.95 Veloz 20 6.45 - -2.84 - 
Rabicip 6.80 77.20 Razo 20 7.39 - -1.90 - 
Results 
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Pan 40 (Pantoprazole) was seen to be the most prescribed brand 
in this study. The cost of pan 40 was reasonable compared to the 
other prescribed brands. However, Omez (Omeprazole) was the 
prescribed brand with least cost. Brand Esomac (Esomeprazole) and 
Rablet 40 & Rabicip (Rabeprazole) were the brands having twice the 
cost than other prescribed brands. 
 
Discussion 
Discussion 
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DISCUSSION 
The majority of patient population was male (69.5%, n=237) with 
remaining being female (30.5%, n=104).  (Table-2). Most of the patients under 
the study were of age from 41-60 years old (42.8%, n=146) (table-1). (Graph-1), 
followed by patients who are in the age of above 60 years old (32.6%, n=111) 
and the remaining of patients was of age of 18-40 years (24.6%, n=84). A similar 
study was conducted by Rajani, Sathisha Aithal et al and reported that patients of 
age between 41 to 60 were the majority group of people who received PPIs same 
as this study. Middle aged group was observed to receive PPIs more than any 
other age groups. 
All patients in the study were selected from two Departments. Among 
that, 216 patients were from gastroenterology (63.3%) and remaining 125 
patients were from Department of surgery (36.7%). Most of the patients were 
included from the Department of Gastroenterology. (table-3), (Graph-3). It is 
observed that PPIs were prescribed most in patients admitted in Department of 
Gastroenterology due to gastric-related issues in them. 
 Among 341 patients in the study, Pan was administered in 308 patients 
(90.3%) followed by Rablet in 18 patients (5.3%), Esomac in 10 patients (2.9%), 
Omez in 4 patients (1.2%) and Rabicip in 1 patient (0.3%). It is observed that a 
greater extent of patients received Pantoprazole. A similar study done by Rajani, 
Sathisha Aithal et al also states that Pantoprazole was the most prescribed PPI in 
their study. Patients who received multiple drug therapy with antibiotics in this 
study received Pantoprazole as well more frequently for the eradication of 
H.Pylori induced Peptic ulcer disease and as prophylactic agent for NSAID 
induced PUD. 
 Out of 341 patients, Indication for giving PPI in 181 Patients were 
received PPIs for Co-morbidity (53.1%) which was majority followed by 
analgesic use in 38 patients (11.1%), Gastritis in 27 patients (7.9%), GERD in 20 
patients (5.9%), Peptic ulcer in 7 patients (2.1%), UGI bleeding in 5 patients 
(1.5%). PPIs were administered in the remaining 59 patients (17.3%) for without 
indications. A similar study was done by Nousheen et al and concluded that most 
Discussion 
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of the patients received PPIs with NSAIDs. But in this study, PPIs were 
administered in most of the patients because of co-morbidity. The indication for 
administering PPIs depends upon the diagnosis and possible issues to be 
occurred. 
The majority of 208 patients out of 341 patients in this study were 
received PPI through intravenous route (61%) and 133 patients received through 
Oral route (39%). Rapid onset of action was achieved by administering 
intravenously. Those patients who received drugs with lesser interacting potential 
were observed to receive PPIs orally. 
Among 341 patients in this study, most of the patients received PPI for a 
duration of 4 days in 65 patients (19.1%) followed by duration of 5 days in 52 
patients (15.2%), duration of 3 days in 43 patients (12.6%), duration of 6 days in 
34 patients (10%), duration of 7 days in 31 patients (9.1%), duration of 2 days in 
29 patients (8.5%), duration of 8 days in 20 patients (5.9%), duration of 9 days in 
13 patients (3.8%) and duration of 1 day in 7 patients (2.1%). Remaining 47 
patients received PPI for 10 days and above up to 21 days. The duration therapy 
depends on the condition and cure rate of the patient received. However, long 
term administration of PPIs may result in serious. 
 Out of 341 patients included, 282 patients received rational 
therapy (82.7%) and 59 patients received irrational therapy (17.3%). A greater 
extent of patients in this study received considerably a rational therapy. Rational 
use of PPIs minimizes the potential risks of drug interactions and other possible 
harm to the subject. 
Pan 40 was the brand among pantoprazole which was of least cost 
available in the hospital. The other available brands; Pantodac, Pantium and 
Pantocid are costlier than the prescribed brand. Esomeprazole was having other 
available brands in the hospital of lesser cost. Brand Reciper injection, Nexpro 
tablet and Sompraz injection were respectively 0.50, 0.75 and 4.50 rupees lesser 
than brand Esomac. Among the available 2 brands in Omeprazole, the prescribed 
brand was Omez which is Rs.0.60 less costly than available Omicap. Rablet 40 
and Rabicip were the brands prescribed for the drug Rabeprazole while other 
Discussion 
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lesser brands were available. Veloz 20 and Razo 20 are respectively Rs.2.84 and 
Rs.1.90 costlier than the prescribed brand. The brands with lesser cost can be 
administered to achieve a cost effective therapy. 
 
Conclusion   
Conclusions 
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CONCLUSION 
 Most of the patients in this study received PPIs from the Gastroenterology 
department because of the Gastric-related disorders. The prescribing pattern has 
to be further monitored to reduce the long term use of PPIs to bring down 
interactions and other possible issues related to PPIs. 
 Pantoprazole was the most prescribed PPI in this study. It was frequently 
administered for the prophylaxis of NSAID induced peptic ulcer. Pantoprazole 
shows no significant interactions with other co-administered drugs and it is the 
PPI available in the hospital with least cost. Hence, it is the best drug of choice 
because of its lowest interaction potential with other medications as well as in 
terms of cost. The duration of PPI administration has to be taken in to account as 
the long term administration may lead to unpredictable issues like hepatic 
dysfunction and higher treatment cost. 
 Even though, there are only considerable differences between PPIs in 
terms of clinical efficacy, the possible drug interactions could be a key factor in 
the selection of PPIs. In addition, utmost care should be taken while 
administering PPIs in patients receiving multiple drugs and other elder patients 
prone to take combination of drugs to attain a rational therapy. PPIs proven to 
have lower risks of drug interaction would be the favorable choice in those 
occasions. 
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Data collection form 
Case no: Ip/Op No: Department 
Age Sex    
Admitted on: Discharged on: 
Complaint at admission: 
 
 
Medical history: 
 
 
 
Medication history: 
 
 
 
Drug allergies: 
 
 
 
Diagnosis: 
 
 
 
Brand name Generic name Dose&freq Date 
           
           
           
           
           
           
           
           
           
           
           
           
           
           
 
Indications of PPI  
Patient under upper gastrointestinal endoscopy  
GERD  
Helicobactor pylori reaction  
Peptic ulcer ;gastric/duodenal/bleeding  
NSAIDs and corticosteroid in older patient  
Dyspepsia  
Increase gastric acid/ ZES/ mastocytosis  
Diagnosis of gastritis  
Prevention of drug induced ulcer  
Aspirin and warfarin /coumadin  
 
PPI name IV Oral Duration Reason 
     
 
 
     
 
 
 
PPI name IV Oral Duration Cost 
     
 
 
 
PPI prescribing pattern Rational  irrational  
 
 


